About Research Studies

Pharmaceutical companies use research studies to learn more about investigational drugs. Research studies help provide more information about how well investigational drugs work and how safe they are.

Using the information collected in research studies, doctors can decide if investigational drugs can one day be approved and made available to the public. By participating in the CROWN study, you will make an important contribution to adult ADHD research.

For more information about the CROWN study, please contact:

Phone (804) 893 - CARE
That's (804) 893 - 2273

www.VirginiaStudy.com

CROWN

10Dec2018_V1_405-201-00014_Subject Brochure_English

20181881
#23423578.0

IRB Approved at the
Protocol Level
Dec 17, 2018

ADHD won't let your focus stay in one place.

If you're living with attention-deficit/hyperactivity disorder (ADHD), learn more about the CROWN research study of an investigational drug for adults with ADHD.

If you're like most people with **ADHD**, starting a project is rarely the problem.

The challenge is seeing it through to the end. Because of ADHD, your focus and attention jump to and from other things and thoughts, making it hard to stay on task.

While there are treatment options available for your ADHD symptoms, these treatments can often be ineffective, result in unwanted side effects, or become difficult to stop using. As a result, the CROWN research study is being conducted to explore additional adult ADHD treatment options.

In the study, doctors are evaluating an oral investigational drug to see if it helps treat symptoms in adults with ADHD. This investigational drug has not been approved in any country to treat adult ADHD and is only available in research studies like this one.

Study doctors want to compare two doses of the investigational drug to a placebo, which is a pill without active medicine that is sometimes called a "sugar pill". The results of this study will provide more information about the investigational drug and whether it could one day be approved by the United States Food and Drug Administration (FDA) to treat ADHD.

Who is eligible to participate in the CROWN study?

To pre-qualify for this study, you must:

- Be 18 to 55 years of age
- Be diagnosed or have been diagnosed with ADHD

All study-related visits, tests, and study drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.

What will happen during the CROWN study?

If you are eligible for this study and agree to participate, you will be randomly assigned (like drawing straws) to receive one of two doses of the investigational drug or placebo. You have a 2 in 3 chance of receiving the investigational drug and a 1 in 3 chance of receiving placebo.

You, the study doctor, and the study staff will not know which study drug (investigational or placebo) you are taking. However, in the event of an emergency, this information can be provided.

As a participant in this study, you will be asked to take your study drug twice a day at the same time each day for 7 weeks. You will also visit the study clinic about 12 times and receive 3 follow-up phone calls in the week after taking the last dose of your study drug. Your total study participation will last up to 13 weeks, which includes screening for eligibility, treatment, and follow-up.

If you complete this study, you could be eligible to participate in a 12-month extension study in which all subjects will receive the investigational drug.

What are the benefits and risks related to the CROWN study?

As with any research study, you may not benefit from participating in this study. However, your participation may help ADHD patients in the future.

It is also possible you could experience one or more side effects during this study. Before you join the study, the study staff will talk with you about all known study-related risks and side effects.

Because this study can affect your health, you will be monitored closely. The sponsor of this study was required to design a protocol. All of the methods and procedures outlined in the protocol were reviewed by an Independent Review Board (IRB) that is responsible for your safety.